Vol. 3 No. 6 (2023)
Reimbursement Reviews

Ravulizumab (Ultomiris)

Published June 8, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses ravulizumab (Ultomiris) 10 mg/mL solution for IV infusion.
  • Indication: For the treatment of adults and pediatric patients with atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy.